Letter · 2016 · Open access
Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse
Annals of Oncology, 27(8), 1652–1653 · Published 31 May 2016 · DOI 10.1093/annonc/mdw189
In brief
“Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse” is a 2016 letter by Henk K. van Halteren, published in Annals of Oncology. OpenAlex counts 1 citations as of 22 November 2026. It is open access: the full text is free to read at Annals of Oncology.
- Citations
- 1
- Most cited in
- 2016 (1)
- References
- 7
- Authors
- 1
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
van Halteren, H. K. (2016). Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse. Annals of Oncology, 27(8), 1652–1653. https://doi.org/10.1093/annonc/mdw189
MLA 9
van Halteren, Henk K. “Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse.” Annals of Oncology, vol. 27, no. 8, 2016, pp. 1652–1653. https://doi.org/10.1093/annonc/mdw189.
Chicago
van Halteren, Henk K. 2016. “Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse.” Annals of Oncology 27 (8): 1652–1653. https://doi.org/10.1093/annonc/mdw189.
Harvard
van Halteren, H. K. (2016) ‘Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse’, Annals of Oncology, 27(8), pp. 1652–1653. doi:10.1093/annonc/mdw189.
IEEE
H. K. van Halteren, “Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse,” Annals of Oncology, vol. 27, no. 8, pp. 1652–1653, 2016, doi: 10.1093/annonc/mdw189.
BibTeX
@article{vanhalteren2016reply,
title = {{Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse}},
author = {van Halteren, Henk K.},
journal = {Annals of Oncology},
year = {2016},
volume = {27},
number = {8},
pages = {1652--1653},
doi = {10.1093/annonc/mdw189},
url = {https://doi.org/10.1093/annonc/mdw189}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- surrogate endpoints
- overall survival
- progression-free survival
- anticancer agents
- regulatory approval
- clinical benefit
- statistical controversies
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
van Halteren, H. K. (2016). Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse. Annals of Oncology, 27(8), 1652–1653. https://doi.org/10.1093/annonc/mdw189
How many times has this paper been cited?
1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of Oncology: sign in and open the full text from this page.
Who wrote this paper?
Henk K. van Halteren.
What is the DOI of this paper?
10.1093/annonc/mdw189, permanently at https://doi.org/10.1093/annonc/mdw189. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.